Clinical trial registry record

Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 17, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04919135
Last registry update
August 17, 2025
Status
Completed
Phase
Phase 1, Phase 2
Sponsor
Vinmec Research Institute of Stem Cell and Gene Technology
Enrollment
158
Countries
Vietnam
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · SINGLE
Evidence population
Human clinical study registration
Participants
158
Population
ALL · 60 Years to 85 Years
Duration
2021-10-19 to 2024-12-30
Intervention
Umbilical Cord Mesenchymal Stem Cells transplantation; standard frailty treatment and supplementary medication
Comparator
Not reported
Outcomes measured
Adverse events and serious adverse events — up to the 9-month period following treatment; Reduced activities — up to the 9-month period following treatment; Slowing of mobility — up to the 9-month period following treatment; reduction of handgrip strength — up to the 9-month period following treatment; exhaustion — up to the 9-month period following treatment; the level of pain in the knee — up to the 9-month period following treatment; respiratory function — up to the 9-month period following treatment; patients' inflammation — up to the 9-month period following treatment; patients' immune — up to the 9-month period following treatment; immunoregulatory properties of umbilical cord-derived mesenchymal stem/stromal cells — up to the 9-month period followi…; Cellular senescence — up to the 9-month period following treatment; metabolic profiles of CD3+ cells — up to the 9-month period following treatment
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Frailty · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

frailty
Read the original source →Export JSON